6533b833fe1ef96bd129b778

RESEARCH PRODUCT

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

Giampero CarosiMichael W. FriedMitchell L. ShiffmanPeter FerenciMonique ChaneacC. SmithDieter HäussingerGeorge MarinosFernando L. GonçalesK. Rajender ReddyMoisés DiagoDaniel DhumeauxAntonio Craxì

subject

medicine.medical_specialtyHepatitis B virusviral hepatitisAlpha interferonPeginterferon-alfaInterferon alpha-2medicine.disease_causeGastroenterologyAntiviral AgentsPolyethylene Glycolschemistry.chemical_compoundpredictabilityInternal medicineRibavirinmedicinechronic hepatitis CHumansProbabilityRetrospective StudiesHepatitis B viruspeginterferon alfa-2a (40 KD)treatmentHepatologyDose-Response Relationship Drugbusiness.industryRibavirinvirus diseasesInterferon-alphaHepatitis CHepatitis C ChronicViral Loadmedicine.diseasedigestive system diseasesRecombinant ProteinsTreatment OutcomechemistryImmunologyRNA ViralDrug Therapy Combinationsustained virological responseViral hepatitisbusinessViral loadPeginterferon alfa-2amedicine.drug

description

Background/Aims: Prediction of sustained virological response (SVR) during treatment would allow clinicians to identify patients most likely to benefit from therapy. Methods: Retrospective analysis of data from 1121 adults with chronic hepatitis C treated for 48 weeks with peginterferon alfa-2a (40 KD) 180 mu g/week plus placebo or ribavirin (1000/1200 mg/day), or interferon alfa-2b 3 MIU three times/week plus ribavirin in a randomized, multinational, study. Results: 67% of patients treated with peginterferon alfa-2a (40 KD)/ribavirin with early virological responses (HCV RNA negative or >= 2 log(10) decrease) at week 12 had SVRs at week 72 (HCV RNA 80 % of the planned ribavirin dose. Conclusions: Early, sustained suppression of HCV replication portends an SVR. Cessation of treatment may be contemplated in patients without a >= 2 log(10) reduction in HCV RNA after 12 weeks. (c) 2005 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

yearjournalcountryeditionlanguage
2005-09-01Journal of hepatology
10.1016/j.jhep.2005.04.009https://pubmed.ncbi.nlm.nih.gov/15990196